Paediatric expansion for Phase 3 PREVENT-19 trial of COVID-19 vaccine NVX-XoV2372

The additional arm of the ongoing PREVENT-19 pivotal trial will evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, a recombinant protein vaccine candidate, in up to 3,000 adolescents aged 12-17 across up to 75 sites in the United States.

Source:

Biospace Inc.